Press Releases

- Three clinical readouts expected in 2018, including data from two randomized Phase 2 studies - - Conference call at 8:30 am ET today - CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined

CAMBRIDGE, Mass. , May 1, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018.   The company will provide an update on Merrimack's recent

CAMBRIDGE, Mass. , April 9, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present preclinical data at the 2018 American Association for Cancer Research (AACR) Annual Meeting,

- Strengthened the randomized Phase 2 SHERLOC study evaluating MM-121 in non-small cell lung cancer by expanding enrollment from 80 to 100 patients - - Dosed the first patient in randomized Phase 2 SHERBOC study evaluating MM-121 in metastatic breast cancer - - Announced the formation of a new

Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year CAMBRIDGE, Mass. , March 12, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it is

CAMBRIDGE, Mass. , March 5, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its fourth quarter and full year 2017 investor conference call and webcast at 8:30 a.m. ET on Monday, March 12, 2018 .

CAMBRIDGE, Mass. , Feb. 26, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has dosed the first patient in its SHERBOC study, a double-blind, placebo-controlled randomized Phase 2

Members include world-renowned experts in biomarker-defined cancers, bioengineering, drug discovery and clinical development CAMBRIDGE, Mass. , Feb. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today

CAMBRIDGE, Mass. , Feb. 15, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that Richard Peters , M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 2018 RBC

CAMBRIDGE, Mass. , Jan. 4, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that Richard Peters , M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 36 th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 , at 9:00